Helix Biopharma Corp. (TSE:HBP) has released an update.
Helix BioPharma Corp., a clinical-stage biopharmaceutical company, has announced the successful filing of its interim financial statements for the first half of the fiscal year ending January 31, 2024. This development has led to the Ontario Securities Commission lifting a previously imposed management cease trade order. The company, which specializes in immune-oncology therapies using its DOS47 technology, continues to progress in its field.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
